profit from every $100 of sales.
$0$100
Orchestra BioMed Holdings
$6.15+2.33% today
+39.1% in 1 year
1-year low $3.491-year high $6.35
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Orchestra BioMed Holdings sold, what it kept, and what it did with the cash.
Sales went from $3.53 million in 2022 to $33.5 million in 2025, with -$52.7 million of profit last year.
SalesProfit
Orchestra BioMed Holdings vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Orchestra BioMed Holdings | No profit yet | ||
 Vertex Pharmaceuticals | 34.8× · Expensive | ||
 Regeneron Pharmaceuticals | 21.8× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.3× · Fair price |
AI analysis
An AI analyst reads Orchestra BioMed Holdings's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 4 | 3 | 3 | 33 | |
| 3 | 3 | 2 | 33 | |
| -33 | -52 | -64 | -52 | |
| -32 | -51 | -64 | -51 | |
| -34 | -49 | -61 | -53 | |
| -1.06 | -1.48 | -1.66 | -1.11 | |
| 94.0% | 93.3% | 92.3% | 99.4% | |
| -924.3% | -1,866.2% | -2,437.5% | -154.7% | |
| -951.3% | -1,779.7% | -2,313.3% | -157.4% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 96 | 95 | 76 | 115 |
| Cash | 20 | 31 | 22 | 35 |
| Total debt | 12 | 2 | 17 | 16 |
| Total liabilities | 43 | 27 | 43 | 61 |
| 53 | 68 | 33 | 54 | |
| 32 | 33 | 37 | 48 | |
| -40.1% | -58.4% | -102.6% | -58.6% | |
| -64.0% | -72.2% | -185.2% | -98.4% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -29 | -46 | -51 | -49 | |
| 1 | 0 | 0 | 0 | |
| -30 | -46 | -51 | -49 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 3 | 8 | 11 | 12 |
Valuation
- –
- –
- –
- 4.9×
- 14.5×
- –
- –
- -10.2%
- -10.9%
- 0.0%
Profitability
- 99.4%
- -154.7%
- -157.4%
- -166.2%
- -62.6%
- -58.4%
- -138.0%
- -54.3%
- -63.2%
- 184.8%
Growth
- +111.6%
- –
- +2.7%
- –
- +17.1%
Financial health
- -0.4×
- 0.03
- 1.5%
- -66.9×
- 7.03
- 7.01
- 0.33
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 4%of 952
Bottom 2%of 883
Top 5%of 870
Bottom 10%of 985
What analysts expect
- Average price target
- $12.00
- Range
- $12.00 – $12.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 12, 2026 | -0.33 | -0.40 | +17.5% |
| Mar 12, 2026 | 0.26 | -0.38 | +168.4% |
| Nov 10, 2025 | -0.40 | -0.38 | −5.3% |
| Aug 12, 2025 | -0.50 | -0.51 | +2.0% |
| Apr 2, 2025 | -0.43 | -0.43 | +0.0% |
| Mar 26, 2025 | -0.37 | -0.43 | +14.0% |
| Nov 12, 2024 | -0.41 | -0.44 | +6.8% |
| Aug 12, 2024 | -0.45 | -0.41 | −9.8% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
33No pass
Benjamin Graham
42No pass
Philip Fisher
48No pass
Peter Lynch
52No pass
Joel Greenblatt
2No pass
Charlie Munger
40No pass
Terry Smith
40No pass
Questions about Orchestra BioMed Holdings
Is Orchestra BioMed Holdings a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Orchestra BioMed Holdings AI analysis
What does Orchestra BioMed Holdings do?
Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. It is in Biotechnology.
Does Orchestra BioMed Holdings pay a dividend?
No. Orchestra BioMed Holdings does not pay a dividend at the moment.
Is Orchestra BioMed Holdings stock halal?
Yes. Orchestra BioMed Holdings passes our halal screen: its business is permitted and its debt is 3% of its market value, under the 30% limit. How we check
How has Orchestra BioMed Holdings stock done over the past year?
Up 39.1% over the past twelve months, to $6.15. It traded between $3.49 and $6.35 and is 3.1% below its high.
Who are Orchestra BioMed Holdings's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Orchestra BioMed Holdings's.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.